The Pharma Data

JULY 27, 2021

Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. About Teneobio Teneobio, Inc.

Production 52

Production Antibody Sales Manufacturing 52

The Pharma Data

OCTOBER 27, 2020

the phase 2 SAPPHIRE study seeks to evaluate the use of autologous endothelial progenitor cells (EPCs) genetically engineered to express endothelial nitric oxide synthase in patients with PAH taking conventional PAH treatments. Conducted by our Canadian affiliate Northern Therapeutics, Inc.,

Production 40

Production Sales Licensing Licensing 40

Drug Discovery World

NOVEMBER 8, 2023

Bredl’s poster looks at genetically engineered macrophages to disrupt the cold tumour microenvironment, and Sobczak’s covers deciphering the structural details of the recognition mode of cancer-associated glycoproteins by siglec receptors implicated in immune suppression in cancer.

Antibody 62

Antibody Engineer Protein Scientist 62

Drug Discovery World

NOVEMBER 9, 2023

Marine Houdou, Genetic Engineering Specialist, Polyplus, on: ‘From modular DNA assembly to recombinant protein production at Polyplus’. Charlotte Deane, PhD, Professor, Structural Bioinformatics, Statistics, University of Oxford; Chief Scientist, Biologics AI, Exscientia, giving a featured presentation on generative antibody modelling.

Engineer 52

Engineer Antibody Protein In-Vivo 52